About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Lupin Gets FDA Approval to Market Generic Irbesartan Tablets in US

by Kathy Jones on October 18, 2012 at 5:55 PM
Font : A-A+

 Lupin Gets FDA Approval to Market Generic Irbesartan Tablets in US

The US Food and Drug Administration has given approval to Lupin Pharmaceuticals to market its Irbesartan tablets, a generic version of Sanofi Aventis's Avapro, in the country.

The company said that it has received approval to market the Irbesartan tablets in 75-300 mg strengths.

Advertisement

The Avapro tablets are used in treating hypertension and nephropathy in type II diabetic patients and accounted for more than $400.7 million in annual sales, according to data from IMS health.


Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
COVID Toes
International Yoga Day 2022 - 'Yoga for Humanity'
Wearable Devices Are Now Transforming Depression, Multiple Sclerosis, and Epilepsy Management.
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Congestive Heart Failure 

Most Popular on Medindia

Indian Medical Journals Daily Calorie Requirements Calculate Ideal Weight for Infants Vent Forte (Theophylline) Find a Hospital Sanatogen A-Z Drug Brands in India Hearing Loss Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Pregnancy Confirmation Calculator

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use